Drugs Made In America Acquisition II Corp.
Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 01 Apr 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 17 Nov 2025, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Drugs Made In America Acquisition II Corp. — Overview & Financial Snapshot
Drugs Made In America Acquisition II Corp. (NasdaqGM: DMII) is a Financial Services company, ranked #3,633 of 6,774 companies globally and #1,611 of 4,000 in United States on PositoAI, with a Positivity Score of 20,388. Its market capitalisation is ₹6,126.94 Cr ($649.10M), P/E ratio is 34.0 and P/B ratio is 1.31. It has no active red flags (PosiRed) and 2 yellow flags (PosiYellow, 6/10 points): Annual report filed late (NT 10-K); Quarterly report filed late (NT 10-Q).
For financial statements, ratio trends and score history, Go Deep →